Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

EyePoint reports positive EYP-1901 trial results for wet AMD

Published 02/04/2024, 09:05 AM
© Reuters.
EYPT
-

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) has announced new subgroup analyses from its Phase 2 DAVIO 2 clinical trial, which highlight the potential of EYP-1901 as a treatment for wet age-related macular degeneration (wet AMD (NASDAQ:AMD)). The data, presented at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting on Sunday, suggest EYP-1901 could alter the treatment paradigm for patients with this retinal disease.

EYP-1901 combines vorolanib, a tyrosine kinase inhibitor, with the bioerodible Durasert E technology for sustained delivery. The subgroup analysis showed numerical superiority in visual acuity and anatomic stability for patients treated with EYP-1901 compared to those given aflibercept, without the need for supplemental injections up to six months.

The Phase 2 DAVIO 2 trial met its primary endpoint, with EYP-1901 demonstrating statistical non-inferiority in visual acuity changes and a favorable safety profile compared to aflibercept. Secondary endpoints were also achieved, notably a significant reduction in treatment burden and strong anatomical control.

EyePoint CEO Jay Duker, M.D., expressed confidence in the data, affirming that the positive outcomes were attributable to EYP-1901. The company plans to initiate Phase 3 trials in the second half of 2024, following discussions with the U.S. Food and Drug Administration (FDA).

Wet AMD is a leading cause of vision loss in individuals over 60, and current treatments require frequent injections. EYP-1901's sustained delivery could reduce this burden, with the recent trial showing up to 88% treatment burden reduction at six months.

EyePoint Pharmaceuticals is also progressing with other clinical milestones for EYP-1901, including a Phase 2 trial in non-proliferative diabetic retinopathy, with topline data expected in the second quarter of 2024.

This report is based on a press release statement from EyePoint Pharmaceuticals. The company is dedicated to the development and commercialization of therapeutics for serious retinal diseases. Its pipeline features the proprietary Durasert E technology for intraocular drug delivery. EyePoint's lead product candidate, EYP-1901, is under investigation for several VEGF-mediated retinal diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.